Update after half-year results
In a well-received announcement that complied with the recent Swiss restrictions on commentary in...
Read moreAGM and recent financing
Kinarus’ Therapeutics AG held its AGM on June 28th. Shareholders approved all proposals,...
Read moreFull Year 2022 Results
Kinarus has published its Annual Report for 2022. The challenging funding environment has delayed...
Read moreFirst transaction on KIN001
Kinarus have announced the signing of an agreement with ChaoDain (Hangzhou) Investment Management...
Read moreReceptive environment for KIN001
Three years after the start of the pandemic investors might be forgiven for thinking that new...
Read moreImplications of recent news flow
The recent news flow on Kinarus’ lead product KIN001 has bolstered its profile for the treatment of...
Read moreStrategic Update
Kinarus has announced a strategic update on the way forward: its focus (and the majority of our...
Read moreKINETIC study results
Kinarus have announced the discontinuation of the Phase 2 KINETIC study of its anti-inflammatory...
Read moreMaking p38 MAP kinase inhibition viable
The inhibition of the validated drug target p38 MAP kinase has been shown by many big...
Read more- Prev
- 1 of 1 pages
Register to be first
Get research on the companies that interest you straight to your inbox
